Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 763 KB, PDF document
Aim To investigate the impact of treatment with once-weekly subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), for up to 2 years in people with type 2 diabetes (T2D) managed in routine clinical practice.Materials and methods The study was based on data from national registries. People who redeemed at least one prescription of semaglutide and had 2 years of follow-up were included. Data were collected at baseline and after 180, 360, 540 and 720 days of treatment (all timepoints +/- 90 days).Results In total, 9284 people redeemed at least one semaglutide prescription (intention-to-treat) and 4132 people redeemed semaglutide continuously (on-treatment). For the on-treatment cohort, the median (interquartile range) age was 62.0 (16.0) years, diabetes duration was 10.8 (8.7) years, and glycated haemoglobin (HbA1c) level was 62.0 (18.0) mmol/mol at baseline. A subset of the on-treatment cohort, comprising 2676 people, had HbA1c measurements at baseline and at least once during 720 days. The mean (95% confidence interval) changes in HbA1c after 720 days were -12.6 (-13.6; -11.6) mmol/mol (P < 0.001) for GLP-1RA-naive people, and -5.6 (-6.2; -5.0) mmol/mol (P < 0.001) for GLP-1RA-experienced people. Similarly, 55% of GLP-1RA-naive people and 43% of GLP-1RA-experienced people reached a HbA1c target of
Original language | English |
---|---|
Journal | Diabetes, Obesity and Metabolism |
Volume | 25 |
Issue number | 6 |
Pages (from-to) | 1740-1749 |
Number of pages | 10 |
ISSN | 1462-8902 |
DOIs | |
Publication status | Published - 2023 |
- database research, GLP-1, glycaemic control, real-world evidence, semaglutide, type 2 diabetes, THERAPEUTIC INERTIA, HYPERGLYCEMIA, MANAGEMENT, UPDATE, SYSTEM, MG
Research areas
ID: 341280478